The alkaloid alstonine: A review of its pharmacological properties

Evidence-based Complementary and Alternative Medicine

Volumn 3, Issue 1, 2006, Pages 39-48

  Elisabetsky, E ^a,c   Costa Campos, L ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c NONE   (Brazil)

Author keywords

Alstonine; Antipsychotic; Ethnopharmacology; Indole alkaloids; Traditional psychiatry

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ALSTONINE; AMPHETAMINE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; DIZOCILPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; INDOLE ALKALOID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PENTOBARBITAL; PICROTOXIN; QUETIAPINE; RESERPINE; RISPERIDONE; SEROTONIN RECEPTOR AFFECTING AGENT; SULPIRIDE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; CATALEPSY; CATATONIA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SAFETY; EPILEPSY; HUMAN; HYPNOSIS; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEIZURE; TRADITIONAL MEDICINE; TRANQUILIZING ACTIVITY;

EID: 33745684513     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nek011     Document Type: Review

References (73)

1. Williams JE. Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on uña de gato and sangre de grado. Altern. Med. Rev. 2001;6:567-79.
2. Cano A, Alcaraz O, Arnao MB. Free radical-scavenging activity of indolic compounds in aqueous and ethanolic media. Anal Bioanal Chem 2003;376:33-7.
3. Cordell GA, Quinn-Beattie ML, Farnsworth NR. The potencial of alkaloids in drug discovery. Phytother Res 2001;15:183-205.
4. Costa-Campos L, Elisabetsky E, Lara DR, Carlson TJ, King SR, Ubilas R, et al. Antipsychotic profile of alstonine: ethnopharmacology of a traditional Nigerian botanical remedy. An Acad Bras Cienc 1999;71:189-201.
5. Iwu MM, Klayman DL. Evaluation of the in vitro antimalarial activity of Picralima nitida extracts. J Ethnopharmacol 1992;36:133-5.
6. Noble RL. The discovery of the vinca alkaloids - chemotherapeutic agents against cancer. Biochem Cell Biol 1990;68:1344-51.
7. Kweifio-Okai G. Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: I. J Ethnopharmacol 1991;33:263-7.
8. Ezeamuzie IC, Ojinnaka MC, Uzogara EO, Oji SE. Anti-inflammatory, antipyretic and anti-malarial activities of a West African medicinal plant - Picralima nitida. Afr J Med Med Sci 1994;23:85-90.
9. Wosu LO, Ibe CC. Use of extracts of Picralima nitida bark in the treatment of experimental trypanosomiasis: a preliminary study. J Ethnopharmacol 1989;25:263-8.
10. Nasser AM, Court WE. Stem bark alkaloids of Rauvolfia caffra. J Ethnopharmacol 1984;11:99-117.
11. Perlman WR, Weickert CS, Akil M, Kleinman JE. Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. J Psychiatry Neurosci 2004;29:287-93.
12. Lyne J, Kelly BD, O'Connor WT. Schizophrenia: a review of neuropharmacology. Ir J Med Sci 2004;173:155-9.
13. Costa-Campos L, Lara DR, Nunes DS, Elisabetsky E. Antipsychotic-like profile of alstonine. Pharmacol Biochem Behav 1998;60:133-41.
14. Bourin M, Poisson L, Larousse C. Piracetam interaction with neuroleptics in psychopharmacological tests. Neuropsychobiology 1986;19:93-96.
15. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78.
16. Ezrin-Waters C, Muller P, Seeman P. Catalepsy induced by morphine and haloperidol: effects of apomorphine and anti-cholinergic drugs. Can J Physiol Pharmac 1976;54:516-9.
17. Moore NA, Blackman A, Awere S, Leander JD. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur J Pharmacol 1993;237:1-7.
18. Jackson DM, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmac Ther 1994;64:291-369.
19. Horacek J. Novel antipsychotics and extrapyramidal side effects: Theory and reality. Pharmacopsychiatry 2000;33 (Suppl 1): 34-42.
20. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
21. Bourin M, Nic Dhonnchadha BA, Colombel MC, Dib M, Hascoët M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 2001;124:87-95.
22. Turnbull G, Bebbington P. Anxiety and the schizophrenic process: clinical and epidemiological evidence. Soc Psvchiatr Epidemiol 2001;36:235-43.
23. 4 receptors and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze. Eur J Pharmacol 1997;335:117-25.
24. Sakamoto H, Matsumoto K, Yukihiro O, Nakumura M. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent. Pharmacol Biochem Behav 1998;60:873-8.
25. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-80.
26. Moore NA. Behavioural pharmacology of the new generation of antipsychotics agents. Br J Psychiatry Suppl 1999;38:5-11.
27. Kennedy B. Experimental approaches to the detection of anxiolytic activity in the rat. Ir J Med Sci 1978;147:38-42.
28. File SE. The contribution of behavioral studies to the neuropharmacology of anxiety. Neuropharmacology 1987;26:877-86.
29. Dalvi A, Rodgers RJ. Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head-dipping but not the disinhibition of open-arm avoidance. Pharmacol Biochem Behav 1999;62:727-34.
30. File SE, Wardill GA. Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacology (Berl.) 1975;44:53-9.
31. Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 1998;350:21-9.
32. Ohl F, Roedel A, Storch C, Holsboer F, Landgraf R. Cognitive performance in rats differing in their inborn anxiety. Behav Neurosci 2002;116:464-71.
33. Nic Dhonnchadha BA, Bourin M, Hascoet M. Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 2003;140:203-14.
34. Isogawa K, Fujiki M, Akiyoshi J, Tsutsumi T, Horinouchi Y, Kodama K, Nagayama H. Anxiety induced by repetitive transcranial magnetic stimulation is suppressed by chronic treatment of paroxetine in rats. Pharmacopsychiatry 2003;36:7-11.
35. Costa-Campos L, Dassoler SC, Rigo AP, Iwu M, Elisabetsky E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol Biochem Behav 2004a;77:481-9.
36. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Chichester: John Wiley and Sons, 1991, 133-58.
37. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244.
38. Costall B, Naylor RJ. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol 1995;116:2989-99.
39. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002;71:555-68.
40. Roth BL, Shapiro DA. Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin Ther Targets 2001;5:685-95.
41. 2C receptors and their atypical regulation properties. Life Sci 2003;72:2429-49.
42. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 2001;21:750-7.
43. Lourenço Da Silva A, Hoffmann A, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003;48:27-30.
44. Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol 2001;420:33-43.
45. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and elevated plus maze. Eur J Pharmacol 1989;169:1-10.
46. Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 2002;43 (Suppl 2): 19-24.
47. Torta R, Monaco F. Atypical antipsychotics and serotonergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 2002;43 (Suppl 2): 8-13.
48. Alldredge BK. Seizures risk associated with psychotropic rugs: clinical and pharmacokinetic consideration. Neurology 1999;53 (Suppl 2): S68-75.
49. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;95:294-330.
50. Cain DP. Long-term potentiation and kindling: how similar are the mechanisms. Trends Neurosci 1989;57:37-43.
51. Costa-Campos L, Iwu M, Elisabetsky E. Lack of pro-convulsant activity of the antipsychotic alkaloid alstonine. J Ethnopharmacol 2004b;93:307-10.
52. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 1998;18:197-209.
53. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297:400-3.
54. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44 (Suppl. 8): S14-23.
55. Meldrum BS. Neurotransmission in epilepsy. Epilepsia 1995;36:S30-35.
56. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998;54:581-618.
57. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev 2000;31:288-394.
58. Rakic P, Bourgeois JP, Goldman-Rakic PS. Synaptic development of the cerebral cortex: implications for learning, memory, and mental illness. Prog Brain Res 1994;102:227-43.
59. Daw NW, Stein PSG, Fox K. The role of NMDA receptors in information processing. Ann Rev Neurosci 1993;16:207-22.
60. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral grey matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992;49:195-205.
61. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003;169:215-33.
62. Maurel-Remy S, Bervoets K, Millan MJ. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5HT2A receptors. Eur J Pharmacol 1995;280:R9-11.
63. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999;141:267-78.
64. Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 1999;34:266-76.
65. 2C receptors. J Pharmacol Exp Ther 2000;295:226-32.
66. Beljanski M, Beljanski MS. Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol 1982;50:79-87.
67. Beljanski M, Beljanski MS. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 1986;43:198-203.
68. Wright CW, Phillipson JD, Awe SO, Kirby GC, Warhurst DC, Quetinleclercq J, Angenot L. Antimalarial activity of criptolepine and some other anhydronium bases. Phytother Res 1996;10:361-63.
69. Gandhi M, Vinayak VK. Preliminary evaluation of extracts of Alstonia scholaris bark for in vivo antimalarial activity in mice. J Ethnopharmacol 1990;29:51-7.
70. Demichel P, Roquebert J. Effects of raubasine stereoisomers on pre- and postsynaptic α-adrenoceptors in the rat vas deferens. Br J Pharmacol 1984;83:505-10.
71. 2-adrenoceptor-mediated pressor response in the pithed rats by raubasine, tetrahydroalstonine and akuammigine. Eur J Pharmacol 1985;106:203-5.
72. Shimazawa M, Chikamatsu S, Morimoto N, Mishima S, Nagai H, Hara H. Neuroprotection by Brazilian Green Propolis against In vitro and In vivo Ischemic Neuronal Damage. Evid Based Complement Alternat Med 2005;2:201-7.
73. Lindequist U, Niedermeyer THJ, Jülich WD. The pharmacological potential of mushroom. Evid Based Complement Alternat Med 2005;2:285-99.